T. Rowe Price Associates’s Evotec EVO Stock Holding History

T. Rowe Price Associates’s Portfolio EVO Stock Details EVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22,188	Closed	-$527K	–	2991
2021 Q4	$527K	Buy	+22,188	New	+$517K	﹤0.01%	2362

Other funds holding EVO

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's EVO Position: Q1 2022 in Review

T. Rowe Price Associates sold out of Evotec (EVO) in Q1 2022, closing a stake of 22,188 shares — an estimated $527K sold.

T. Rowe Price Associates first reported a position in EVO in Q4 2021 and held it in 1 quarter. The position peaked at $527K in Q4 2021. 22 funds tracked by Wall St. Rank hold EVO as of Q1 2022.

T. Rowe Price Associates reported no remaining Evotec position as of Q1 2022 after selling out during the quarter.
T. Rowe Price Associates sold 22,188 Evotec shares in Q1 2022, an estimated $527K.
T. Rowe Price Associates first reported a position in Evotec in Q4 2021 and held it in 1 quarter.
T. Rowe Price Associates's Evotec position peaked at $527K in Q4 2021.
22 funds tracked by Wall St. Rank held Evotec as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.